A Prospective study to evaluate the incidence of Erythroblastemia associated with Natalizumab in patients with relapsing remitting Multiple Sclerosis

Trial Profile

A Prospective study to evaluate the incidence of Erythroblastemia associated with Natalizumab in patients with relapsing remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jul 2017 New trial record
    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top